Insmed (INSM)
(Delayed Data from NSDQ)
$74.50 USD
+0.07 (0.09%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $74.48 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Insmed, Inc. [INSM]
Reports for Purchase
Showing records 1 - 20 ( 120 total )
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Views on Clinical Progress in the Respiratory Field
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal ASPEN Trial Delivers For Brensocatib - Our Thoughts; Reit. Buy, Increasing PT to $70
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Positive Topline TPIP Safety and Tolerability Data - Optimistic on Near-Term Phase 3 ASPEN Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Expected 2Q24 Catalysts For Phase 3 ASPEN Trial and TPIP; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for INSM 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Dose Titration and Safety Insights Support TPIP - As ARISE Advances Arikayce With PRO Validation; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
ARISE Trial Delivers With Respiratory PRO - Setting Stage for ENCORE; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
2023 As the Year of Near-Term Catalysts, Arikayce Growth; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Turning New Page For Translational Pillar-Gene Therapy and Rare Disease Upside; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Arikayce Global Expansion and 2023 Catalysts For Broader Pipeline; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Arikayce Opportunity Beyond Refractory-PRO Validation Expected 1H23; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Arikayce Delivers for the Quarter-Pipeline Opportunities for 2022 Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Highlights: Insights into the PAH Commercial & Clinical Landscape
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Considerations on TPIP Ahead of Phase 2a Readout YE22 and Brensocatib Utility
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A